Royalty Pharma’s $2 Billion Debt Offering Could Be a Game Changer for RPRX

• On September 3, 2025, Royalty Pharma plc announced it had priced an offering of US$2.0 billion in senior unsecured notes, including US$600 million due 2031, US$900 million due 2035, and US$500 million due 2055, with proceeds intended for general corporate purposes.
• This major debt financing move highlights Royalty Pharma's focus on enhancing its capital structure and capacity to pursue new investment opportunities in the biopharmaceutical sector.
• We’ll explore how this large-scale notes offering could influence Royalty Pharma’s ability to fund future royalty acquisitions and portfolio growth.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Royalty Pharma Investment Narrative Recap

To be comfortable as a Royalty Pharma shareholder, you generally need to believe in the company's ability to deploy capital efficiently as a leading acquirer of biopharmaceutical royalties, in a space shaped by ongoing innovation. The US$2.0 billion senior unsecured notes offering strengthens Royalty Pharma's funding flexibility but does not materially change the immediate stakes for the main short term catalyst, which remains the acquisition of attractive new royalty streams, nor does it address the most significant current risk: the ongoing Vertex royalty dispute that could impact revenue and earnings. A recent announcement closely tied to this new debt raise is the US$2 billion funding arrangement with Revolution Medicines, where Royalty Pharma committed up to US$1.25 billion in synthetic royalties on daraxonrasib. This partnership showcases Royalty Pharma’s continuing push to invest in high-potential assets and aligns directly with its efforts to capture new, long-duration royalties, a key growth catalyst highlighted by analyst consensus. By contrast, investors should be aware that even with substantial new capital, uncertainty from the Vertex royalty dispute remains unresolved and could still affect...

Read the full narrative on Royalty Pharma (it's free!)

Royalty Pharma's narrative projects $4.0 billion revenue and $922.7 million earnings by 2028. This requires 20.0% yearly revenue growth and a decrease in earnings of $77.3 million from current earnings of $1.0 billion.

Uncover how Royalty Pharma's forecasts yield a $44.86 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Six individual fair value estimates from the Simply Wall St Community span a broad range from US$28 to US$181, reflecting significant variation in investor outlooks. Competition among royalty acquirers, highlighted in recent analyst commentary, may place extra pressure on sourcing high-return deals and ultimately impact Royalty Pharma’s future earnings profile.

Explore 6 other fair value estimates on Royalty Pharma - why the stock might be worth 21% less than the current price!

Build Your Own Royalty Pharma Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Royalty Pharma research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Royalty Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Royalty Pharma's overall financial health at a glance.

No Opportunity In Royalty Pharma?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com